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Correlation between SPINK5 Gene Mutations and
Clinical Manifestations in Netherton Syndrome
Patients
Nahoko Komatsu1,2,3, Kiyofumi Saijoh4, Arumugam Jayakumar5, Gary L. Clayman5, Mikiko Tohyama6,
Yasushi Suga7, Yuki Mizuno7, Katsuhiko Tsukamoto8, Katsushige Taniuchi9, Kazuhiko Takehara3 and
Eleftherios P. Diamandis1,2
Netherton syndrome (NS) is a congenital ichthyosiform dermatosis caused by serine protease inhibitor Kazal-
type 5 (SPINK5) mutations. Tissue kallikreins (KLKs) and lymphoepithelial Kazal-type-related inhibitor (LEKTI)
(SPINK5 product) may contribute to the balance of serine proteases/inhibitors in skin and influence skin barrier
function and desquamation. SPINK5 mutations, causing NS, lead to truncated LEKTI; each NS patient possesses
LEKTI of a different length, depending on the location of mutations. This study aims to elucidate genotype/
phenotype correlations in Japanese NS patients and to characterize the functions of each LEKTI domain. Since
we were unable to demonstrate truncated proteins in tissue from patients with NS, we used recombinant
protein to test the hypothesis that the length of LEKTI correlated with protease inhibitory activity. Genotype/
phenotype correlations were observed with cutaneous severity, growth retardation, skin infection, stratum
corneum (SC) protease activities, and KLK levels in the SC. Predominant inhibition by LEKTI domains against
overall SC protease activities was trypsin-like (Phe-Ser-Arg-) activity by LEKTI domains 6–12, plasmin- and
trypsin-like (Pro-Phe-Arg-) activities by domains 12–15, chymotrypsin-like activity by all domains, and furin-like
activity by none. KLK levels were significantly elevated in the SC and serum of NS patients. These data link LEKTI
domain deficiency and clinical manifestations in NS patients and pinpoints to possibilities for targeted
therapeutic interventions.
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INTRODUCTION
Netherton syndrome (NS) (OMIM 256500) is an autosomal
recessive disorder caused by mutations in the serine protease
inhibitor Kazal-type5 (SPINK5) gene (Chavanas et al., 2000).
NS presents as an ichthyosiform dermatosis with variable
erythroderma, hair-shaft defects (bamboo hair), atopic
features, and growth retardation (Griffiths et al., 1998).
Lymphoepithelial Kazal-type-related inhibitor (LEKTI) (Ma-
gert et al., 1999), the product of SPINK5 (Chavanas et al.,
2000), includes in its primary structure 15 different serine
protease inhibitory domains (Magert et al., 1999). The
inhibitory functions of LEKTI are highly diverse, that is,
toward trypsin, plasmin, subtilisin A, cathepsin G, and
human neutrophil elastase (Mitsudo et al., 2003). LEKTI is
expressed in the normal stratum corneum (SC), stratum
granulosum, and skin appendages (Bitoun et al., 2003;
Raghunath et al., 2004). Partial LEKTI domains, for example,
1–6, 6–90, 9–12, 12–15, 6, or 15, display distinct inhibitory
profiles (Jayakumar et al., 2004; Egelrud et al., 2005;
Schechter et al., 2005; Borgono et al., 2007), implying that
each LEKTI domain may possess a selective/specific inhibi-
tory function.
Human tissue kallikreins (KLKs) are a family of 15 trypsin
or chymotrypsin-like secreted serine proteases (KLK1–KLK15)
(Yousef and Diamandis, 2001). At least eight KLKs are
expressed in normal skin (Komatsu et al., 2005b, 2006a).
KLKs are colocalized with LEKTI in skin (Ekholm et al., 2000;
Bitoun et al., 2003; Komatsu et al., 2005a). In addition, KLKs
and LEKTI are secreted together in lamellar bodies to the
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intercellular space, in the uppermost stratum granulosum
(Sondell et al., 1995; Ishida-Yamamoto et al., 2004, 2005).
KLKs are capable of cleaving corneodesmosomes, and their
enzymatic activities are suppressed by partial recombinant
LEKTI domains (Simon et al., 2001; Caubet et al., 2004;
Egelrud et al., 2005; Schechter et al., 2005; Borgono et al.,
2007). Overall trypsin-like and/or chymotrypsin-like activities
are considerably elevated in the skin of SPINK5-deficient
mice (Descargues et al., 2005) and in NS patients (Komatsu
et al., 2002; Hachem et al., 2006). The elevated activities
cause increased degradation of corneodesmosomal cadherins
in NS patients (Descargues et al., 2006). Altogether, these
accumulating data strongly suggest that, in skin, (1) KLKs are
desquamation-related serine proteases; (2) LEKTI may be a
negative regulator of KLKs/other proteases and overall
protease activities; and (3) the balance between serine
proteases and inhibitors, for example, KLKs and LEKTI, may
be essential, not only for steady desquamation but also for
normal skin barrier function.
A unique characteristic of NS patients is that premature
stop codon mutations in SPINK5 are sufficient to cause this
disease. NS patients are thought to synthesize truncated
LEKTI with fewer inhibitory domains (Sprecher et al., 2001;
Bitoun et al., 2002; Komatsu et al., 2002), and they always
lack some domains encoded downstream from the premature
stop codons. Since different mutations are predicted to
generate different truncated LEKTI variants, each NS patient
possesses a different truncated LEKTI. It is thus conceivable
that there might be a correlation between genotype and
phenotype in NS, depending on the location of the mutations.
For example, an NS patient with a shorter LEKTI (fewer
inhibitory domains) might present with a severe phenotype,
while a patient with further downstream mutations (and
longer LEKTI) could present with a milder phenotype. In fact,
our previous study hinted to a correlation between genotype
and severity of skin lesions and SC protease activity in
Japanese NS patients (Komatsu et al., 2002).
Two new studies have demonstrated a correlation
between cutaneous phenotype (the severity of skin lesion)
and serine protease activities in skin, residual LEKTI expres-
sion and degradation of desmoglein1/desmocollin1 in the
skin of NS (Descargues et al., 2006; Hachem et al., 2006).
However, a correlation between genotype and phenotype
was not established. Therefore, this study aimed to (1)
elucidate a possible genotype and phenotype correlation in
NS; (2) reveal which clinical features are linked to the
genotype; (3) verify the correspondence between the
inhibitory profiles of LEKTI domains and the SC protease
activities in NS patients; (4) clarify a potential correlation
between genotype and KLK levels; and (5) propose indivi-
dualized therapy according to patient’s genotype.
RESULTS
Correlations between SPINK5 gene mutations and clinical
manifestations in NS patients
Five patients diagnosed as NS due to gene mutations in
SPINK5, from five unrelated Japanese families, were studied
(Patients A–E) (Table 1). All SPINK5 mutations led to a
premature stop codon, and predicted a production of
truncated LEKTI. Since we were unable to demonstrate
truncated proteins in tissue from patients with NS, we used
recombinant protein to test the hypothesis that the length of
LEKTI correlated with protease inhibitory activity. Patients
A–D or Patient E displayed compound heterozygous or
homozygous mutations, respectively. Each patient was
predicted to possess a different number of LEKTI domains
(Table 1). To date, 10 different and non-related families have
been diagnosed/reported as NS according to SPINK5 gene
mutations in Japan (data not shown). Eight out of 10 families
displayed heterozygote Y126X mutation in exon 5 (including
our Patients A–D). Six families (including Patient D) and one
other family (Patient E) had heterozygote or homozygote
R790X mutation in exon 25, respectively. The most frequent
pattern of compound heterozygote mutations was Y126X/
R790X, which were found in four families (including Patient D).
All other mutations have been detected only once (data not
shown).
Various clinical symptoms can accompany NS, for
example, growth retardation, bamboo hair, or atopic features
(Griffiths et al., 1998). We examined whether these clinical
features are correlated with the genotype, that is, the number
of remaining LEKTI domains. We found the following: (1)
clinical features that could be correlated with the genotype
were cutaneous severity, including the palms/soles region
(Figure 1), pain/irritation in denuded skin, growth retardation,
frequency of skin infections, and general condition after birth;
(2) clinical features that could not be correlated with the
genotype were occurrence or severity of allergic diseases
(including the levels of eosinophils and IgE in blood),
bamboo hair, pruritus, sweat secretion, and temperature
instability (Table 1).
In these patients, cutaneous bleeding and blistering was
not experienced; oral mucosa, nails, and teeth were intact
and no apparent physical, neurological, or mental dysfunc-
tion was reported. Sexual dysfunction was not determined
(Table 1). All patients were aware of low sweat secretion and
temperature instability, especially during the summer.
Inhibitory profile of partial recombinant LEKTI domains toward
various SC enzymatic activities
Several clinical manifestations were found to correlate with
the genotype of NS patients, indicating that some of the
missing inhibitory functions of downstream LEKTI domains
could not be compensated by the remaining (upstream)
domains. To further examine this issue, we prepared four
different partial recombinant LEKTI domains as follows: LEKTI
domains 1–6, domains 6–90 (full domains 6–8 plus partial
domain 9), domains 9–12, and domains 12–15. Five different
SC activities were selected for evaluation, for the following
reasons: the overall SC trypsin-like (Phe-Ser-Arg-; FSR-) and
chymotrypsin-like (Arg-Pro-Tyr-) activities are required
for desquamation (Suzuki et al., 1996). LEKTI domain
15 displays anti-plasmin activity (Egelrud et al., 2005),
suggesting the presence of SC plasmin-like (Val-Leu-Lys-)
activity. Several KLKs exhibit differences in their kinetic
preferences between trypsin-like FSR- and trypsin-like
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PFR- (Pro-Phe-Arg-) activities (Oka et al., 2002; Magklara
et al., 2003; Michael et al., 2005; Luo et al., 2006). Furin-like
(Arg-X-Lys-Arg-) activity may contribute to the processing of
LEKTI pro-protein to individual LEKTI domains (Seidah and
Chretien, 1999; Komatsu et al., 2002; Mitsudo et al., 2003).
Thus, the inhibitory properties of each LEKTI fragment toward
the overall SC protease activities were investigated using
normal SC samples (Table 2), and the aforementioned
substrates.
When 125–150ng per mg of SC dry weight of the specified
LEKTI fragment was co-incubated with SC samples, FSR
activity declined to B50%, compared to control activity
(Table 2). A higher amount of LEKTI domains 6–90 and 9–12
(250 ngmg1) reduced the activity to B30%. PFR activity
was significantly attenuated by domains 12–15 in a dose-
dependent manner, whereas other domains suppressed the
activity only slightly. Plasmin-like activity was inhibited
significantly by domains 12–15 only (residual activity
B60%), but without a dose–response effect. Furin-like
activity was not significantly suppressed by any of the
domains. Chymotrypsin-like activity was suppressed signifi-
cantly by all domains, in a dose-dependent manner and with
a similar magnitude of inhibition (residual activityB70–40%)
(Table 2).
We then examined if the observed inhibition by LEKTI
fragments was due to unprocessed LEKTI fragments (comprising
Table 1. Clinical features of NS patients from five unrelated Japanese families
Netherton syndrome (age
at time studied, gender)
Patient A
(10 years, female)
Patient B
(1 year, female)
Patient C
(21 years, female)
Patient D
(7 years, male)
Patient E
(7 years, male)
Stop codon mutations in
SPINK5
375delAT/715insT 375delAT/966insC 375delAT/1621G to T 375delAT/2368C to T 2368C to T
Exon 5/exon 9 Exon 5/exon 11 Exon 5/exon 18 Exon 5/exon 25 Exon 25/exon 25
Stop codons in LEKTI Y126X/C-D239-
244L-X
Y126X/G-E323-
342R-X
Y126X/E541X Y126X/R790X R790X/R790X
Domain 2/domain 4 Domain 2/domain 5 Domain 2/domain 8 Domain 2/domain 120 Domain 120/domain
120
LEKTI domains retained Domains 1–4 Domains 1–5 Domains 1–8 Domains 1–120 Domains 1–120
Cutaneous features
Non-palm/sole region Consistent
erythroderma
Consistent
erythroderma
Consistent
erythroderma
Focal (occasionally
erythroderma)
Focal (occasionally
erythroderma)
Palms/soles Severe peeling Mild peeling No lesion No lesion No lesion
Lichenification No Yes (joints) Yes (joints) Yes (joints) Yes (joints)
Pain/irritation in denuded
Skin
Yes Yes Yes Slight Slight
Percutaneous absorption Over-absorption Unknown Unknown Unknown Unknown
Frequent skin infection Yes Yes Yes Occasionally No
General condition Good or lethal Good Good Good Good
Growth retardation o3 SD B3 SD o3 SD B2 SD B2 SD
Height (cm) at 7.5 years 95 — 98 112 104
Weight (kg) at 7.5 years 16 — 17 21 17
Current height and weight
Age at time measured
(years)
10.2 0.6 18 7.5 7.5
Current height (cm) 105 58 131 112 104
Current weight (kg) 20 5.5 38 21 17
Allergic diseases Asthma Urticaria Not apparent Food allergy Not apparent
Laboratory findings
Eosinophil (mm3) 91 1,206 400 1,089 3,280
IgE (IU per ml) 32,488 17 8,497 5,590 3,411
Clinical course No improvement Improved with age Improved with age Improved with age Improved with age
Reference Hanakawa et al.,
2005
Mizuno et al., 2006 Komatsu et al., 2002 Tsukamoto et al.,
2003
Komatsu et al., 2002
LEKTI, lymphoepithelial Kazal-type-related inhibitor; NS, Netherton syndrome; SD, standard deviation; SPINK5, serine protease inhibitor Kazal-type 5.
Patient A experienced life-threatening systemic infections around her neonatal to early infantile period; however, her general condition is recently good.
Patient A only has experienced the death of her sibling around neonatal phase by NS with the complication of systemic infections (Hanakawa et al., 2005).
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several domains) or by individual domains, after LEKTI
proteolysis (Figure 2). LEKTI domains were not significantly
processed up to 3 hours of incubation, an interval that is as
long as the duration of the enzymatic assay. Thus, the
inhibitory activities shown in Table 2 are likely mediated by
unprocessed LEKTI. Proteolytic processing of LEKTI to
individual domains may not be necessary for its inhibitory
function. LEKTI fragments were significantly degraded after
24 hours, yielding smaller fragments (Figure 2).
Correlation between genotypes and overall SC protease
enzymatic activities in NS patients
The diversity of LEKTI inhibitory functions demonstrated in
Table 2 suggests that NS patients could display variable
overall SC protease activity, corresponding to their genotype
(due to lack of downstream LEKTI inhibitory domains). To test
this possibility, we measured the overall SC protease
activities in skin extracts from NS patients (Table 3).
Trypsin-like (FSR- and PFR-) activities were high in
patients with upstream SPINK5 mutations (Patients A–C)
(Table 3). The chymotrypsin-like activity was not elevated in
any patients, except for the aggravated skin lesion in Patient
B. Plasmin- and furin-like activities were significantly
elevated in all patients, except Patient A (on two occasions,
these activities were not determined due to sample deple-
tion). The aggravated lesion in Patient B seems to exhibit
higher enzymatic activities than the stable lesion of the same
patient or lesions of other patients (Table 3).
Correlation between genotypes and KLK levels in the SC or
serum of NS patients
The balance of serine proteases and their inhibitors, including
KLKs and LEKTI, is important for regulation of skin
desquamation (Ekholm et al., 2000; Descargues et al.,
2005; Komatsu et al., 2005b; Hachem et al., 2006). Since
NS patients are deficient in some inhibitory LEKTI domains,
they may present with alterations in KLK concentrations
or activities in the SC or serum. Thus, KLK levels were
measured in the SC and serum of these five patients by ELISAs
(Tables 4 and 5).
In the SC (Table 4a), chymotrypsin-like KLK7 levels ranged
widely among the five patients. In Patients A and B, the
elevation of KLKs 5, 8, and 11 was quite significant. For
Patients C–E, the most pronounced increases were for KLKs 6,
8, 10, and 13 (Table 4a). In the aggravated skin lesion (Table
4b), KLK levels were, in general, higher than those in the
stable lesion. The differences were particularly notable for
KLKs 6, 10, 13, and 14 (Table 4b).
In serum (Table 5), where both KLKs and LEKTI are present
(Magert et al., 1999; Yousef and Diamandis, 2001), KLKs in
NS patients tended to be higher than those in the normal
subjects. The elevation of total trypsin-like KLKs was more
pronounced than that of chymotrypsin-like KLKs. KLK11
levels did not differ significantly among all the patients
b
Figure 1. Palm and plantar lesions in NS patients. (a) Patient A (7 years).
Patients A and B have consistently displayed scaling and peeling in their
palms and soles. The lesion in Patient B was much milder that that in
Patient A. In contrast, Patients C–E had no palm/plantar lesions (Table 1).
(b) Patient E (2 years). Generally, the lesions in palms and soles were absent or
much milder than those in non-palm and plantar lesions. Thus, NS patients
are highly likely to display a ‘‘linear scaling’’ at the border between the palms/
soles (the SC appears to be almost intact) and non-palms/soles (the SC is
over-desquamated). We confirmed the ‘‘linear scaling’’ for all patients
(Patients A–E); therefore, the ‘‘linear scaling’’ could be a potential specific
finding in NS.
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Figure 2. Proteolytic degradation of LEKTI domains by SC proteases.
The specified LEKTI domain, domains 1–6 (a), domains 6–90 (b), domains
9–12 (c), and domains 12–15 (d), was incubated with normal SC. The amount
of LEKTI added was 500 ng per mg dry weight for LEKTI domains 6–90, 9–12,
and 12–15 and 600ngmg1 for domains 1–6. Endogenous LEKTI (no
recombinant protein was added) was undetectable (negative). When each
LEKTI domain was incubated without SC sample, degradation was negligible
at any time point (Borgono et al., 2007). Arrows indicate the full length of
each domain and asterisks show the fragments which did not exist at
0minute. The detection Abs were monoclonals 1C11G6 (for domains 1–6,
6–90, and 9–12) and 1D6G8 (for domains 12–15) (Raghunath et al., 2004). The
smaller fragments appeared after incubation, suggesting presence of specific
LEKTI cleavage sites by SC proteases.
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compared to the normal subjects. Also, the elevation of
serum KLKs in Patient E was milder than that of the other
patients (Table 5).
DISCUSSION
In Japanese NS patients, cutaneous severity seems to
correlate with the genotype (Table 1). The generalized
erythroderma of variable intensity in NS (Griffiths et al.,
1998) may be explained by the diversity of SPINK5 mutations
in NS. A sister of Patient A with NS (with stop codon
mutations in exon 2/exon 4) (Hanakawa et al., 2005) and
members of Turkish families with a homozygote mutation in
exon 3 (Bitoun et al., 2002) died from the disease. In contrast,
Patients B–E did not have any life-threatening complication so
far. Despite the potential lethality of SPINK5 mutations in
Patient A, the SC protease activities or KLK levels were not
necessarily much different in comparison to the other patients
(Tables 3–5). Presumably, Patient A might have developed an
alternative regulatory pathway of protease activities during
her life.
Allergic reactions, and/or eosinophil counts and IgE levels
in blood do not seem to be linked to the genotype of NS
patients. Patient C and her brother (who also suffered from
NS) never experienced any allergic reactions, and a
significant elevation of eosinophil/IgE did not appear until
adolescence (Komatsu et al., 2002). Therefore, the emer-
gence of allergic features could be due to secondary factors.
The pathogenesis of growth retardation in NS is not
known. A common finding is absence of a significant
abnormality in the serum level of human growth hormone
(hGH). It is known that hGH is proteolytically processed by
serine proteases (such as plasmin and thrombin) in both the
pituitary and the periphery (Baumann, 1991; Garcia-Barros
et al., 2000). KLKs (KLKs 5–8 and 10–14) and SPINK5 are
Table 2. Inhibition of the overall SC enzymatic activities by LEKTI domains
Residual overall stratum corneum enzymatic activity (mean7SEM (%))
LEKTI domain
Substrate
Amount of LEKTI domain
(ng per mg dry weight) Domains 1–6 Domains 6–90 Domains 9–12 Domains 12–15
Trypsin-like activity 125–150 58.173.5# 46.374.0# 53.973.3# 59.572.5#
Phe-Ser-Arg-AMC 250–300 46.374.1# 28.472.5*1,*2,# 29.872.5*1,*2,# 52.674.0#
500–600 NC NC NC NC
Trypsin-like activity 125–150 NC NC NC 75.375.5#
Pro-Phe-Arg-AMC 250–300 83.971.9# 84.374.0# 88.675.8# 64.573.1*3,#
500–600 NC NC NC 38.774.4*4,#
Chymotrypsin-like activity 125–150 67.574.4# 59.372.1# 69.872.2# 56.974.0#
Arg-Pro-Tyr-pNA 250–300 37.077.4# 36.673.6# 39.173.9# 39.876.6#
500–600 NC NC NC NC
Plasmin-like activity 125–150 NC NC NC 59.777.2#
Val-Leu-Lys-AMC 250–300 90.973.3 96.575.6 88.072.5# 66.475.9*5,#
500–600 NC NC NC 60.176.3#
Furin-like activity 125–150 NC NC NC NC
Pyr-Arg-Thr-Lys-Arg-AMC 250–300 92.671.8 91.372.1 96.171.6 92.472.6
500–600 NC NC NC NC
Residual overall SC enzymatic activities (released AMC or pNA with LEKTI domain divided by released AMC or pNA without LEKTI domain (control)) are
indicated as (mean7SEM (%)). The measurement was performed at 3 or 4 hours time point, for AMC or pNA, respectively. The amount of LEKTI domain to
be added in the assay was determined according to the molecular weight (Figure 2); 250 or 300 ng per mg dry weight for LEKTI domains 6–90, 9–12, and
12–15, or domains 1–6, respectively. When SC sample or LEKTI domain was boiled for 5minutes before the assay started, the protease activity or inhibitory
function was completely lost, respectively (data not shown).
#Significant differences by t-test between the activity with the specified LEKTI domain and the activity without the domain (Po0.01). Significant differences
(t-test or one-way analysis of variance with Bonferroni0s multiple comparison test as a post hoc test, Po0.05) were detected as follows: (*1), the residual FSR
activities using the specified LEKTI domain (250 ngmg1 vs 125 ngmg1); (*2), the residual FSR activities using the specified domain (250 ngmg1) vs
domains 1–6 (300 ngmg1) or 12–15 (250 ngmg1); (*3), the residual PFR activity using domains 12–15 (250 ngmg1) vs the other domains
(250–300 ngmg1); (*4), the residual PFR activity using domains 12–15 (4500ngmg1 vs 125 or 250 ngmg1); (*5), the residual plasmin-like activity
using domains 12–15 (250 ngmg1) vs the other domains (250–300 ngmg1). NC, no change in comparison to 250–300 ngmg1 LEKTI.
AMC, 7-amino-4-methyl-coumarin; LEKTI, lymphoepithelial Kazal-type-related inhibitor; PNA, para-nitroanilide; SC, stratum corneum.
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expressed in the pituitary and appear to be localized to hGH-
producing cells. KLKs 4–6, 8, 13, and 14 were able to cleave
hGH, yielding various isoforms, in vitro. Inhibitor LEKTI
fragments were able to suppress the activity of KLKs 4, 5, and
14 in vitro (Komatsu et al., 2007a). Based on these data, we
recently proposed that LEKTI and KLKs might be involved in
the regulation of growth hormone processing. In NS, hGH
may be proteolytically over-processed by proteases, due to
LEKTI inhibitory dysfunction (deficiency) in the pituitary. This
could lead to over-fragmentation of the hormone and loss of
its bioactivity (Komatsu et al., 2007a). According to this
suggestion, patients with upstream SPINK5 mutations should
present with more severe growth retardation. In support of
this, Patient A displayed the most severe growth retardation
among the five patients (Table 1). Thus, the involvement of
LEKTI in the regulation of hGH proteolysis is likely.
In the enzymatic assays of overall SC protease activities
(Table 2), LEKTI domains, particularly domains 6–90 and 9–12,
displayed strong inhibitory properties against trypsin-like
FSR-activity. Patients D and E (who possess domains 6–120)
displayed only a slight elevation of FSR-activity (Table 3). We
could thus conclude that LEKTI domains 6–12 are essential for
the inhibition of FSR-activity in the SC. Hence, a therapeutic
intervention aiming to suppress FSR-activity in the SC may be
effective in patients who possesso12 LEKTI domains, that is,
Patients A–C.
Both FSR- and PFR-substrates represent trypsin-like acti-
vity. However, the inhibition by LEKTI fragments was
different (Table 2), suggesting that the proteases representing
each activity may be different.
Based on their kinetic properties, KLKs 5, 6, 8, 11, and 13
may affect both FSR- and PFR-activities (Oka et al., 2002;
Magklara et al., 2003; Kapadia et al., 2004; Michael et al.,
2005; Luo et al., 2006). The inhibitory profile of LEKTI
domains toward KLKs 5, 6, and 13 (Schechter et al., 2005;
Borgono et al., 2007) was comparable to the profile toward
FSR-activity, but dissimilar to the activity toward PFR-activity
(Figure 3). Therefore, in the SC, the enzymatic activities of
these KLKs may be contributing mainly to FSR-activity. In
addition, KLK enzymatic activities seem to be regulated by
upstream LEKTI domains (domains 1–12) with the exception
of KLK5 (Figure 3).
The responsible enzymes for PFR-activity are not known,
but all five patients still lacked domains 12–15, which
predominantly inhibit PFR-activity (Table 2). Hence, ther-
apeutically, it may be justified to control the PFR-activity in
the SC of these patients.
LEKTI domains 12–15 exhibit significant inhibition toward
PFR- and plasmin-like activities, unlike the other domains
(Table 2). We thus hypothesize that domains 12–15 may
possess a specific inhibitory role, uncompensated by other
LEKTI domains.
LEKTI domain 15, but not domain 6, is able to suppress
plasmin (Egelrud et al., 2005); most patients displayed a
significant elevation of plasmin-like activity, probably due to
absence of domain 15 (Table 3). Suppression of plasmin-like
activity in the SC may be a fruitful therapeutic strategy for all
NS patients.
None of LEKTI domains significantly suppressed the SC
furin-like activity (Table 2), which may be responsible for the
Table 3. SC enzymatic activities in NS patients
Netherton syndrome
Patient A Patient B Patient C Patient D Patient E Patient B
Substrate (released AMC or pNA;
nmol per mg dry weight) Normal Aggravated
Trypsin-like activity
Phe-Ser-Arg-AMC 15.571.5 41.51 52.01 54.51 12.5 25.01 ND
Pro-Phe-Arg-AMC 5.773.1 13.01 8.4 13.71 4.2 8.3 17.91
Chymotrypsin-like activity
Arg-Pro-Tyr-pNA 13.975.5 9.2 ND 5.9 13.8 11.7 75.31
Plasmin-like activity
Val-Leu-Lys-AMC 1.771.0 2.1 5.51 ND 3.71 4.91 10.61
Furin-like activity
Pyr-Arg-Thr-Lys-Arg-AMC 3.071.3 4.4 ND 21.71 27.41 23.41 43.61
AMC, 7-amino-4-methyl-coumarin; pNA, para-nitroanilide; SC, stratum corneum; SD, standard deviation; NS, Netherton syndrome; ND, not determined
due to the sample depletion.
1Significant differences (Po0.05) between the mean of normal samples and each patient at the specified time (Smirnov test for extreme values). The data for
normal controls were referred from a previous study (Komatsu et al., 2005b, 2006b). For Patient B, two different samples were used for the assay, obtained at
different times: (1) at a stable phase and (2) an aggravated phase. The SC samples in the aggravated lesion were not available for the other four patients.
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proteolytic processing of pro-LEKTI into 15 individual
inhibitory domains (Seidah and Chretien, 1999; Komatsu
et al., 2002; Mitsudo et al., 2003). Hence, the processing of
pro-LEKTI may be independent from LEKTI inhibition of
protease activity. The data of Figure 2 suggest that proteolysis
of pro-LEKTI to individual domains is not essential for the
domains’ inhibitory functions. The increased furin-like
activity in NS patients (Table 3) may help in the release of
more LEKTI domains, which might provide a more efficient
inhibitory activity compared to unprocessed LEKTI.
The SC chymotrypsin-like activity was not significantly
elevated in NS patients (Table 3), whereas SPINK5-deficient
mice displayed significant elevation of chymotrypsin-like
activity in their skin (Descargues et al., 2005). KLKs 7 and 14
may be the major players of chymotrypsin-like proteases/
activity in the SC (Felber et al., 2005; Komatsu et al., 2005b,
2007a). Altogether, it is possible that (1) the same chymo-
trypsin-like enzymes (e.g., KLKs 7 and 14) might be targeted
by all LEKTI domains tested. Thus, upstream LEKTI domains
may be sufficient in regulating their activity; and/or (2)
another inhibitor (e.g., a2-macroglobulin family) (Galliano
et al., 2006) may be compensating for the missing LEKTI
functions in these patients. These interpretations might also
explain the normal chymotrypsin-like activity (Table 3),
despite increased KLK7 levels (Table 4a) in the SC of
these patients. It seems that in NS patients, the SC
chymotrypsin-like activity is not as important as other
activities, such as FSR-, PFR-, or plasmin-like activities.
In the SC (Table 4a), the levels of trypsin-like KLKs 5, 8, and
11 were particularly high in Patients A and B. Also, trypsin-like
Table 4. KLK levels in the SC of NS patients by ELISA
(a)
KLK (ng per mg dry weight) Normal Patient A Patient B Patient C Patient D Patient E
Mean7SD
Chymotrypsin-like KLK
KLK7 10.976.0 57.81 11.0 34.71 57.51 13.1
Trypsin-like KLKs
KLK11 8.774.1 20.21 20.71 16.0 8.1 15.3
KLK8 5.871.8 21.81 21.81 16.81 8.7 11.51
KLK5 3.171.4 17.81 11.81 4.2 7.41 3.6
KLK10 0.6770.41 0.20 1.2 4.21 5.81 1.4
KLK14 0.3470.13 0.24 0.38 0.28 0.10 0.41
KLK6 0.2870.12 0.11 0.16 49.41 25.41 0.841
KLK13 0.1770.14 0.831 0.04 20.11 7.21 1.11
Total of Trypsin-like KLKs 19.175.4 61.21 56.11 111.01 62.71 34.21
(b)
KLK (ng per mg dry weight) Normal Patient B Patient E
Mean7SD Aggravated Aggravated
Chymotrypsin-like KLK
KLK7 10.976.0 11.0 32.91 13.1 14.1
Trypsin-like KLKs
KLK11 8.774.1 20.71 22.11 15.3 12.4
KLK8 5.871.8 21.81 20.61 11.51 36.81
KLK5 3.171.4 11.81 9.31 3.6 0.64
KLK10 0.6770.41 1.2 28.71 1.4 2.11
KLK14 0.3470.13 0.38 4.51 0.41 4.81
KLK6 0.2870.12 0.16 74.61 0.841 10.21
KLK13 0.1770.14 0.04 41.31 1.11 16.41
Total of Trypsin-like KLKs 19.175.4 56.11 201.01 34.21 83.31
KLK, kallikrein; NS, Netherton syndrome; SD, standard deviation; SC, stratum corneum.
Data for normal subjects were referred from a previous study (Komatsu et al., 2005b). KLKs were subdivided into chymotrypsin-like KLK (KLK7) and trypsin-
like KLKs (the rest of KLKs) (Yousef and Diamandis, 2001).
1Smirnov test detected significant differences between the normal SC subjects and individual patients (Po0.05). For Patients B and E, data from two different
samples are shown, that is, (1) stable and (2) aggravated lesions (Table 4b), which correspond to data described in Table 3. SC samples in aggravated phase
were not available for the other three patients.
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KLKs 6, 10, and 13 tended to be low in Patients A–C. There
might be some correlation between the SC trypsin-like KLK
levels and disease genotype, although multiple LEKTI domains
were able to suppress multiple KLKs (Figures 4 and 5).
KLKs 6, 13, and 14 were notably elevated in the
aggravated skin lesion (Table 4b). Since these KLK elevations
were also observed in psoriatic skin lesions (Komatsu et al.,
2007b), the elevations could represent a secondary phenom-
enon. In general, the aggravated skin tended to display higher
SC protease activities and KLK levels, compared to the stable
lesion (Tables 3 and 4b).
Most KLKs were lower in Patient E than Patient D (Tables 4
and 5), although both patients possess LEKTI domains 1–120
(Table 1). Thus, compound heterozygote vs homozygote
mutations in SPINK5 could affect KLK expression.
In conclusion, we provide early evidence for genotype and
phenotype correlations in Japanese NS patients. The correla-
tions are between cutaneous severity, growth retardation,
Table 5. KLK levels in the serum of NS patients by ELISA
KLK (ngml1) Normal Patient A Patient B Patient C Patient D Patient E
Mean7SD
Chymotrypsin-like KLK
KLK7 5.172.1 16.41 32.01 14.41 26.01 11.61
Trypsin-like KLKs
KLK6 4.471.5 15.91 10.61 15.31 9.61 5.0
KLK8 1.970.77 15.81 27.71 15.81 17.61 9.41
KLK10 1.270.56 6.01 11.81 8.21 10.81 2.0
KLK5 0.6870.15 2.91 3.61 2.91 3.41 1.41
KLK11 0.5470.16 0.64 0.56 0.34 0.36 0.76
KLK14 0.2270.091 1.21 1.21 0.401 0.501 0.741
KLK13 o0.01 0.751 0.571 1.61 0.891 0.401
Total of Trypsin-like KLKs 9.071.6 43.31 56.01 44.61 43.11 19.81
KLK, kallikrein; NS, Netherton syndrome; SD, standard deviation.
1Smirnov test showed significant differences between the normal subjects and individual patients (Po0.05). The amount KLK13 in normal samples is very
low or undetectable; KLK13 in normal serum was reported as o0.01 ngml1 without SD. Total of trypsin-like KLKs indicates the sum of trypsin-like KLKs.
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Figure 3. Genotype and phenotype correlations in NS patients. The SPINK5 gene consists of 33 exons, encoding 15 LEKTI inhibitory domains (Magert et al.,
1999; Chavanas et al., 2000). LEKTI domains 2 and 15 (highlighted) are characterized as Kazal-type domains; the rest are non-Kazal-type domains (Magert et al.,
1999). In general, exons with odd numbers contain 128 nt (GenBank accession no. NP_006837) and encode the conserved inhibitory domain; the even number
exons encode connecting amino-acid chains with the exceptions of Kazal-type domains 2 and 15. The remaining LEKTI domains for individual patients are
indicated by the gray bars. The severity of clinical features was evaluated based on the information described in Table 1. Dotted lines are a predicted correlation.
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frequency of skin infection, the overall SC protease activities,
and KLK levels in the SC. The altered KLK expression in the
SC of NS patients suggests presence of a regulatory system
that controls gene expression of proteases and their inhibitors
(SPINK5 and KLKs) in skin tissue.
MATERIALS AND METHODS
Patients and SPINK5 gene mutation analysis
Informed consent was obtained from all patients, their parents, and
normal volunteers. Our studies were performed according to the
Declaration of Helsinki Principal. The Medical Ethics Committee of
the Graduate School of Medical Science, School of Medicine,
Kanazawa University approved all described studies.
Five patients from five unrelated Japanese families were studied
(Patients A–E) (Table 1) (Komatsu et al., 2002; Tsukamoto et al.,
2003; Hanakawa et al., 2005; Mizuno et al., 2006). SPINK5 gene
mutation analysis was performed using standard methods for all the
patients. Details of these gene mutations are described elsewhere
(Komatsu et al., 2002).
Sample preparation of the SC and serum
The SC samples were obtained from the forearm of the patients
and 25 normal volunteers (20–35 years of age; a mix of males
and females), by stripping using NichibanTM tape (Nichiban,
Tokyo, Japan). The SC samples were washed and purified using
toluene. After toluene treatment, the purified samples were
air-dried and weighed. The detailed procedure for purification is
described elsewhere (Komatsu et al., 2005b). The data for
normal subjects (for both the SC and serum) shown in Tables 3–5
were referred from our previous studies (Komatsu et al., 2005b,
2006b).
Preparation of recombinant LEKTI domains and anti-LEKTI
antibodies
Recombinant LEKTI domains containing intact LEKTI domains 1–6,
domains 6–90 (containing domains 6–8 and partial domain 9),
domains 9–12, and domains 12–15 were produced in a baculovirus/
insect cell line system as reported previously (Jayakumar et al., 2004;
Schechter et al., 2005; Borgono et al., 2007). Anti-LEKTI mAbs
1C11G6 and 1D6G8 were produced as described previously
(Raghunath et al., 2004).
Immunofluorometric ELISA for human tissue KKLs
With the exception of Fuso-FB6MA53 anti-KLK11 antibody (Ab),
which was purchased (Fuso, Osaka, Japan), all other monoclonal
and polyclonal anti-kallikrein Abs were developed in our laboratory
(Komatsu et al., 2005a). Each of the Abs displayed negligible cross-
reactivity with other KLKs (data not shown). The detailed procedures
and conditions for sample preparation and each KLK ELISA assay are
described elsewhere (Komatsu et al., 2005b).
SC enzymatic activity in Netherton syndrome patients
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Figure 4. Correlation between LEKTI domain function and SC enzymatic activities in NS patients (see also Figure 3 for additional explanations). (a) Summary of
SC enzymatic activities in NS patients, (b) and residual SC activities after suppression by LEKTI domains using normal SC samples. For the suppression of
SC enzymatic activity, we present the results with the lowest residual activity, regardless of the amount of LEKTI domains added (Table 2). The distinct inhibitory
function of partial LEKTI domains seems to be related to the SC protease activities in NS patients. For example, in the SC, some LEKTI domains, particularly
domains 6–90 and 9–12, displayed strong inhibitory properties against trypsin-like FSR-activity (b), suggesting that LEKTI domains 6–12 are essential for the
inhibition of FSR-activity in the SC. The strong inhibition by LEKTI domains 6–12 against FSR-activity may explain why Patients D and E (who possess domains
6–120) displayed only a slight elevation of FSR-activity (a). All five patients lacked domains 12–15, which predominantly inhibit trypsin-like PFR-activity (b).
This may explain why PFR-activity is likely to show a significant elevation in NS patients (a).
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Assay of SC protease enzymatic activities
The synthetic peptide substrates Boc-Phe-Ser-Arg-AMC (AMC,
7-amino-4-methyl-coumarin), Boc-Pro-Phe-Arg-AMC, Boc-Pyr-Arg-
Thr-Lys-Arg-AMC, and Boc-Val-Leu-Lys-AMC (BACHEM, Torrance,
CA) were used at 0.1mM final concentration. MeO-Suc-Arg-Pro-Tyr-
pNA-HCl (pNA, para-nitroanilide) (Chromogenix, Milano, Italy) was
used at 0.4mM final concentration.
The SC samples (0.5mg dry weight) were mixed with 10 ml
of N,N-dimethylformamide, 240ml of 0.1% Triton X-100, 175 ml
of 0.2M Tris-HCl buffer (pH 8.0), and 50 ml of either 1mM
AMC substrates or 4mM of pNA substrate (Komatsu et al., 2005b)
at 41C. Then, the mixture was incubated at 371C with shaking for
1–4 hours (Table 3). Released AMC was measured using a
fluorescence spectrophotometer (Wallac Victor2 1420 Multilabel
Counter, Perkin Elmer, Boston, MA). Released pNA was measured
spectrophotometrically at 405 nm (Wallac Victor2 1420 Multilabel
Counter). Due to the limited amount of samples, each assay was
performed only once per subject, but all measurements were
repeated three times.
Inhibition assay of SC protease enzymatic activities
The mixture comprising 0.5mg dry weight of SC sample, 10 ml of
N,N-dimethylformamide, 240 ml of 0.1% Triton X-100, and 175ml of
0.2 M Tris-HCl buffer (pH 8.0) was incubated at 41C overnight with
shaking. After incubation, the mixture was centrifuged, and the
supernatant/extract was collected at 41C.
Eighty-five microliters of the SC extract/supernatant (correspond-
ing to the extraction of approximately 0.1mg of the SC), the specified
AMC substrate (0.1mM final concentration), and the specified
amount of LEKTI domain were all mixed at 41C. Then, the volume
was adjusted to 100 ml with 0.01% of phosphate-buffered saline at
41C. The mixture was incubated at 371C with shaking for 1–3 hours
and the released AMC was measured. For the pNA substrate, a
similar procedure as the measurement of SC protease activity was
applied. That is, the specified LEKTI domain was added into the
same mixture as the SC protease activity assay at 41C. Then, the
reaction mixture with LEKTI domain was incubated at 371C with
shaking for 2–4 hours, and the released pNA was measured. Each
inhibition assay per each substrate, with the specified amount of
LEKTI domain, was repeated at least four times. However, due to
limited sample availability, the individuals tested with each substrate
were not always the same.
The residual enzymatic activity (expressed as ratio of released
AMC or pNA with LEKTI domain/released AMC or pNA without
LEKTI domain) was calculated for each individual. We evaluated the
residual activity at 1, 2, and 3 hours time points for AMC. The data at
2 and 3hours were highly comparable, with a small standard
error among samples, while the 1 hour data varied widely (data
not shown). Hence, the 3 hours data were adopted for further
evaluation. For pNA substrate, the 4 hours data were used, for the
same reason.
Detection of LEKTI domains by immunoassay
The SC sample (0.5mg dry weight) was mixed with 10 ml of N,N-
dimethylformamide, 240ml of 0.1% Triton X-100, and 175 ml of 0.2 M
Tris-HCl buffer (pH 8.0) at 41C. An amount of LEKTI domain (500 or
600 ng per mg dry weight for LEKTI domains 6–90, 9–12 and 12–15,
or domains 1–6, respectively) was added into the mixture, and the
volume was adjusted to 500 ml with 0.01% phosphate-buffered
saline at 41C. The mixture with LEKTI domains was incubated for
different time points ranging from 0minute to 24 hours at 371C with
shaking. At each time point, the mixture was centrifuged, then 25 ml
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Figure 5. Suppression of KLK activity by LEKTI domains and KLK expression in NS patients (see also Figure 3 for additional explanations). (a) Summary of
KLK levels in the SC of NS patients, (b) and suppression of KLK enzymatic activity by LEKTI domains. Data for suppression of KLK enzymatic activity were
derived from previous studies (Schechter et al., 2005 for KLK7 and Borgono et al., 2007 for the rest of KLKs). Upstream LEKTI domains tend to show
strong inhibition toward individual KLKs (b). However, no evident correlation was observed between inhibition by LEKTI domains toward KLKs and KLK
expressions in NS patients (Table 5).
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(corresponding toB25 or 30mg of undigested LEKTI domain) of the
supernatant was collected. As primary Abs, 1C11G6 or 1D6G8
mAbs (Raghunath et al., 2004) were used for the detection of LEKTI
domains 1–6, 6–90, and 9–12, or 12–15, respectively. Further detailed
procedures for western blotting are described elsewhere (Komatsu
et al., 2005a). For each LEKTI domain, the assay was performed three
times using three different individual samples. However, due to a
limited amount of samples, the individuals tested with different
domains were not always the same.
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